Christopher P. Fox

8.3k total citations
129 papers, 2.4k citations indexed

About

Christopher P. Fox is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Christopher P. Fox has authored 129 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Pathology and Forensic Medicine, 52 papers in Genetics and 51 papers in Oncology. Recurrent topics in Christopher P. Fox's work include Lymphoma Diagnosis and Treatment (80 papers), Chronic Lymphocytic Leukemia Research (38 papers) and CNS Lymphoma Diagnosis and Treatment (32 papers). Christopher P. Fox is often cited by papers focused on Lymphoma Diagnosis and Treatment (80 papers), Chronic Lymphocytic Leukemia Research (38 papers) and CNS Lymphoma Diagnosis and Treatment (32 papers). Christopher P. Fox collaborates with scholars based in United Kingdom, United States and France. Christopher P. Fox's co-authors include Kate Cwynarski, Martin Rowe, Per Ljungman, Catherine Cordonnier, Dan Engelhard, Walter J. F. M. van der Velden, Jan Styczyński, Rafael de la Cámara, Elizabeth H. Phillips and Jelena Mann and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Christopher P. Fox

119 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher P. Fox United Kingdom	27	1.2k	929	663	496	481	129	2.4k
Theodoros P. Vassilakopoulos Greece	26	1.6k 1.3×	1.6k 1.7×	728 1.1×	445 0.9×	733 1.5×	167	3.1k
Juan‐Manuel Sancho Spain	23	821 0.7×	807 0.9×	539 0.8×	431 0.9×	206 0.4×	162	1.8k
Tamar Tadmor Israel	27	730 0.6×	723 0.8×	695 1.0×	133 0.3×	604 1.3×	133	1.9k
Naoto Tomita Japan	21	1.0k 0.8×	627 0.7×	546 0.8×	475 1.0×	218 0.5×	130	1.8k
Patrick Lutz France	26	354 0.3×	490 0.5×	472 0.7×	264 0.5×	326 0.7×	62	2.3k
Gino Santini Italy	25	1.1k 0.9×	899 1.0×	447 0.7×	370 0.7×	249 0.5×	86	2.0k
Marı́a Dolores Caballero Spain	32	1.4k 1.1×	1.2k 1.3×	586 0.9×	348 0.7×	657 1.4×	74	2.8k
G.J. Ossenkoppele Netherlands	34	812 0.7×	1.1k 1.2×	677 1.0×	170 0.3×	607 1.3×	84	3.3k
Krzysztof Warzocha Poland	26	1.1k 0.9×	672 0.7×	999 1.5×	76 0.2×	857 1.8×	169	2.6k
Dennis Cooper United States	27	670 0.5×	1.1k 1.2×	256 0.4×	140 0.3×	466 1.0×	112	2.8k

Countries citing papers authored by Christopher P. Fox

Since Specialization

Citations

This map shows the geographic impact of Christopher P. Fox's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher P. Fox with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher P. Fox more than expected).

Fields of papers citing papers by Christopher P. Fox

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher P. Fox. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher P. Fox. The network helps show where Christopher P. Fox may publish in the future.

Co-authorship network of co-authors of Christopher P. Fox

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher P. Fox. A scholar is included among the top collaborators of Christopher P. Fox based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher P. Fox. Christopher P. Fox is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bielack, Stefan, Carole Soussain, Christopher P. Fox, et al.. (2024). A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment. Journal of Cancer Research and Clinical Oncology. 150(10). 441–441. 6 indexed citations

Advani, Ranjana H., Michael Dickinson, Christopher P. Fox, et al.. (2024). SKYGLO: A Global Phase III Randomized Study Evaluating Glofitamab Plus Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients with Large B-Cell Lymphoma (LBCL). Blood. 144(Supplement 1). 1718.1–1718.1. 6 indexed citations

Abhishek, Abhishek, Matthew J. Grainge, Tim Card, et al.. (2024). Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. RMD Open. 10(1). e003980–e003980. 3 indexed citations

Zinzani, Pier Luigi, Eric D. Jacobsen, Jasmine Zain, et al.. (2024). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial. Blood. 144(Supplement 1). 3061–3061. 4 indexed citations

Abhishek, Abhishek, Matt Stevenson, Georgina Nakafero, et al.. (2023). Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies. British Journal of Dermatology. 190(4). 559–564. 2 indexed citations

Salles, Gilles, Christopher P. Fox, Anthony Wang, et al.. (2023). Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison. Blood. 142(Supplement 1). 1733–1733.

Nakafero, Georgina, Tim Card, Matthew J. Grainge, et al.. (2023). Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation. EClinicalMedicine. 64. 102213–102213. 3 indexed citations

Martínez‐Calle, Nicolás, et al.. (2022). Rare central nervous system lymphomas. British Journal of Haematology. 197(6). 662–678. 7 indexed citations

Fox, Christopher P., Matthew J. Ahearne, Ruth Pettengell, et al.. (2021). Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline. British Journal of Haematology. 196(3). 507–522. 17 indexed citations

10.

Martínez‐Calle, Nicolás, Mark Bishton, Rocío Figueroa, et al.. (2021). Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. British Journal of Haematology. 195(4). 561–570. 7 indexed citations

11.

Hillmen, Peter, Rebecca H. Boucher, Nichola Webster, et al.. (2020). Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. Blood. 136(Supplement 1). 17–18. 13 indexed citations

12.

Sorigué, Marc, Mark Bishton, Eva Domingo‐Doménech, et al.. (2019). Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. Leukemia & lymphoma. 60(10). 2524–2531. 3 indexed citations

13.

Hillmen, Peter, Andy C. Rawstron, Kristian Brock, et al.. (2019). Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. Journal of Clinical Oncology. 37(30). 2722–2729. 180 indexed citations

14.

Hillmen, Peter, Talha Munir, Andy C. Rawstron, et al.. (2017). Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy. Blood. 130. 428–428. 25 indexed citations

15.

Eyre, Toby A., et al.. (2017). Idelalisib-Rituximab Results in Considerable Toxicity but Induces Durable Clinical Remissions in Patients with TP53 Disrupted B Cell Prolymphocytic Leukemia. Blood. 130. 4068–4068.

16.

Fearn, Amy, Christopher P. Fox, Fiona Oakley, et al.. (2017). The NF-κB1 is a key regulator of acute but not chronic renal injury. Cell Death and Disease. 8(6). e2883–e2883. 16 indexed citations

17.

Burns, David, Sohail Rana, Elizabeth Martin, et al.. (2016). Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transplantation. 51(6). 825–832. 35 indexed citations

18.

Fullard, Nicola, Paul A. Townsend, Christopher P. Fox, et al.. (2011). The NF-κB Subunit c-Rel Stimulates Cardiac Hypertrophy and Fibrosis. American Journal Of Pathology. 180(3). 929–939. 68 indexed citations

19.

Shetty, Shishir, Andrew Holt, Wing‐Kin Syn, et al.. (2008). Haematological malignancies presenting with acute liver injury: a single-centre experience. QJM. 101(12). 949–953. 2 indexed citations

20.

Fox, Christopher P., Annabel McMillan, Mark Bishton, Alexandria Porcia Haynes, & Nigel H. Russell. (2008). IVE (ifosfamide, epirubicin and etoposide) is a more effective stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for lymphoma. British Journal of Haematology. 141(2). 244–248. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact